BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

Core Viewpoint - BioCryst Pharmaceuticals, Inc. will report its fourth quarter 2024 financial results on February 24, 2025, and will host a conference call to discuss these results and provide a corporate update [1]. Company Overview - BioCryst Pharmaceuticals is a global biotechnology company focused on improving the lives of individuals with complement-mediated and other rare diseases [3]. - The company utilizes structure-guided drug design to develop first-in-class or best-in-class small-molecule and protein therapeutics aimed at challenging diseases [3]. - BioCryst has commercialized ORLADEYO® (berotralstat), which is the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies [3].